| Pharmaceutical Information |
| Drug Name |
Letermovir |
| Drug ID |
BADD_D02502 |
| Description |
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients [L1021]. It represents the first entry into a new class of CMV anti-infectives, DNA terminase complex inhibitors [A31290]. Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis [L1021]. |
| Indications and Usage |
For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label]. |
| Marketing Status |
Not Available |
| ATC Code |
J05AX18 |
| DrugBank ID |
DB12070
|
| KEGG ID |
D10801
|
| MeSH ID |
C000588473
|
| PubChem ID |
45138674
|
| TTD Drug ID |
D0G8PA
|
| NDC Product Code |
0006-3076; 50473-0126; 50473-0127; 0006-3075; 0006-5003; 69497-0128; 0006-5004 |
| Synonyms |
letermovir | Prevymis | AIC246 |
|
| Chemical Information |
| Molecular Formula |
C29H28F4N4O4 |
| CAS Registry Number |
917389-32-3 |
| SMILES |
COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O
)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
